Physician

Mitchell Dane Martin, MD

According to 2025 Medicare claims, Mitchell Martin, MD (NPI: 1639179708) practices medical oncology in the Knoxville, TN market, with the plurality of this provider's patient population coming from Knox, TN. This provider's primary affiliated billing organization is TENNESSEE CANCER SPECIALISTS PLLC (NPI: 1841228871; TIN: 200677400) and primary practice location at 37932-3366.

Martin's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,228 traditional Medicare patients, billed 461,015 HCPCS/CPT codes, and received $10,092,940 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,649 prescription claims across 536 beneficiaries totaling $8,527,964 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 12 claims. Open Payments data shows 149 records totaling $3,236. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,491,747 to $10,092,940. Similarly, Part D prescription costs have moved sharply higher in recent years, from $2,420,195 to $8,527,964. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $8,145 to $620.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	582	264,695	$2,491,747
2016	642	392,548	$4,990,716
2017	738	417,101	$5,366,767
2018	805	442,727	$6,988,880
2019	792	516,101	$7,823,947
2020	725	484,452	$8,148,046
2021	833	516,506	$8,215,655
2022	1,093	477,617	$8,679,867
2023	1,171	453,733	$8,622,801
2024	1,228	461,015	$10,092,940

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	283	1,792	$2,420,195
2016	334	2,092	$2,910,102
2017	362	2,154	$3,239,736
2018	419	2,189	$4,090,840
2019	423	2,310	$4,300,734
2020	423	2,193	$4,198,038
2021	459	2,320	$6,031,238
2022	469	2,115	$6,978,773
2023	498	2,465	$8,298,685
2024	536	2,649	$8,527,964

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	11	111	$9,290
2016	N/R	178	$35,887
2017	N/R	130	$21,901
2018	N/R	124	$10,013
2019	14	176	$13,156
2020	N/R	122	$6,101
2021	N/R	24	$2,022
2022	N/R	51	$2,795
2023	N/R	42	$7,291
2024	N/R	12	$226

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	655	1,365	$86
82728	Ferritin (blood protein) level	530	999	$13
80053	Blood test, comprehensive group of blood chemicals	968	2,901	$10
36415	Insertion of needle into vein for collection of blood sample	964	3,218	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	990	3,517	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	73	2,044	$994,499
Ibrance	Palbociclib	63	1,770	$950,209
Pomalyst	Pomalidomide	54	1,386	$820,902
Erleada	Apalutamide	53	1,590	$801,053
Tagrisso	Osimertinib Mesylate	38	1,140	$607,752

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	149	$3,236	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mitchell Dane Martin, MD?

Tedicare shows public-source Medicare data for Mitchell Dane Martin, MD (NPI 1639179708), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mitchell Dane Martin, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mitchell Dane Martin, MD?

Mitchell Dane Martin, MD is linked to TENNESSEE CANCER SPECIALISTS PLLC (billing NPI 1841228871) in the available physician profile data.

Does Mitchell Dane Martin, MD have Open Payments data?

Mitchell Dane Martin, MD has 149 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.